Overcoming promoter competition in packaging cells improves production of self-inactivating retroviral vectors
- PMID: 16763662
- DOI: 10.1038/sj.gt.3302807
Overcoming promoter competition in packaging cells improves production of self-inactivating retroviral vectors
Abstract
Retroviral vectors with self-inactivating (SIN) long-terminal repeats not only increase the autonomy of the internal promoter but may also reduce the risk of insertional upregulation of neighboring alleles. However, gammaretroviral as opposed to lentiviral packaging systems produce suboptimal SIN vector titers, a major limitation for their clinical use. Northern blot data revealed that low SIN titers were associated with abundant transcription of internal rather than full-length transcripts in transfected packaging cells. When using the promoter of Rous sarcoma virus or a tetracycline-inducible promoter to generate full-length transcripts, we obtained a strong enhancement in titer (up to 4 x 10(7) transducing units per ml of unconcentrated supernatant). Dual fluorescence vectors and Northern blots revealed that promoter competition is a rate-limiting step of SIN vector production. SIN vector stocks pseudotyped with RD114 envelope protein had high transduction efficiency in human and non-human primate cells. This study introduces a new generation of efficient gammaretroviral SIN vectors as a platform for further optimizations of retroviral vector performance.
Similar articles
-
Equal potency of gammaretroviral and lentiviral SIN vectors for expression of O6-methylguanine-DNA methyltransferase in hematopoietic cells.Mol Ther. 2006 Feb;13(2):391-400. doi: 10.1016/j.ymthe.2005.08.012. Epub 2005 Oct 12. Mol Ther. 2006. PMID: 16226060
-
Generation of a packaging cell line for prolonged large-scale production of high-titer HIV-1-based lentiviral vector.J Gene Med. 2005 Jun;7(6):818-34. doi: 10.1002/jgm.726. J Gene Med. 2005. PMID: 15693055
-
Self-inactivating retroviral vectors with improved RNA processing.Gene Ther. 2004 Nov;11(21):1568-78. doi: 10.1038/sj.gt.3302309. Gene Ther. 2004. PMID: 15372067
-
Retroviral vector production in the National Gene Vector Laboratory at Indiana University.Gene Ther. 2005 Oct;12 Suppl 1:S28-35. doi: 10.1038/sj.gt.3302613. Gene Ther. 2005. PMID: 16231053 Review.
-
Gammaretroviral vectors: biology, technology and application.Viruses. 2011 Jun;3(6):677-713. doi: 10.3390/v3060677. Epub 2011 Jun 3. Viruses. 2011. PMID: 21994751 Free PMC article. Review.
Cited by
-
Gene therapy of MPL deficiency: challenging balance between leukemia and pancytopenia.Mol Ther. 2010 Feb;18(2):343-52. doi: 10.1038/mt.2009.233. Epub 2009 Oct 20. Mol Ther. 2010. PMID: 19844195 Free PMC article.
-
A self-inactivating gamma-retroviral vector reduces manifestations of mucopolysaccharidosis I in mice.Mol Ther. 2010 Feb;18(2):334-42. doi: 10.1038/mt.2009.236. Epub 2009 Oct 20. Mol Ther. 2010. PMID: 19844196 Free PMC article.
-
Self-inactivating alpharetroviral vectors with a split-packaging design.J Virol. 2010 Jul;84(13):6626-35. doi: 10.1128/JVI.00182-10. Epub 2010 Apr 21. J Virol. 2010. PMID: 20410274 Free PMC article.
-
Vector design for expression of O6-methylguanine-DNA methyltransferase in hematopoietic cells.DNA Repair (Amst). 2007 Aug 1;6(8):1187-96. doi: 10.1016/j.dnarep.2007.03.017. Epub 2007 May 7. DNA Repair (Amst). 2007. PMID: 17482894 Free PMC article. Review.
-
Tissue inhibitor of metalloproteinases-1 induces a pro-tumourigenic increase of miR-210 in lung adenocarcinoma cells and their exosomes.Oncogene. 2015 Jul;34(28):3640-50. doi: 10.1038/onc.2014.300. Epub 2014 Sep 29. Oncogene. 2015. PMID: 25263437
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical